Table 7.
Univariable and multivariable logistic regression analyses of factors associated with clinical outcomes.
| Variable | Univariable OR (95% CI) | p | Multivariable aOR (95% CI) | p |
|---|---|---|---|---|
| Outcome 1: CGI-I score of 1–2 at last recorded follow-up (550/650) | ||||
| Age 4–10 years | Reference | Reference | ||
| Age 11–14 years | 0.36 (0.16–0.81) | 0.013 | 0.37 (0.17–0.83) | 0.016 |
| Age 15–17 years | 0.25 (0.11–0.53) | <0.001 | 0.28 (0.13–0.61) | 0.001 |
| Female sex | 0.86 (0.55–1.33) | 0.497 | – | |
| Prior antidepressant trial | 0.39 (0.23–0.65) | <0.001 | 0.46 (0.27–0.78) | 0.004 |
| Off-label prescribing | 0.99 (0.60–1.61) | 0.954 | – | |
| Any adverse effect | 1.03 (0.61–1.73) | 0.919 | – | |
| CGI-S moderately ill (vs mildly) | 1.32 (0.52–3.36) | 0.561 | – | |
| CGI-S markedly ill (vs mildly) | 1.88 (0.70–5.08) | 0.213 | – | |
| Major depressive disorder | 0.94 (0.61–1.46) | 0.796 | – | |
| Generalised anxiety disorder | 1.23 (0.75–2.04) | 0.415 | – | |
| ADHD | 0.75 (0.48–1.18) | 0.210 | – | |
| Psychiatric comorbidity | 0.68 (0.41–1.13) | 0.139 | – | |
| Concomitant treatment‖ | 0.01 (0.00–0.04) | <0.001 | – | |
| Outcome 2: Off-label prescribing (486/650) | ||||
| Age 4–10 years | Reference | – | ||
| Age 11–14 years | 0.72 (0.43–1.21) | 0.220 | – | |
| Age 15–17 years | 0.66 (0.40–1.09) | 0.105 | – | |
| Female sex | 0.78 (0.54–1.12) | 0.177 | – | |
| Prior antidepressant trial | 1.17 (0.69–2.00) | 0.561 | – | |
| CGI-I score of 1–2 | 0.99 (0.60–1.61) | 0.954 | – | |
| Psychiatric comorbidity | 0.99 (0.67–1.47) | 0.972 | – | |
| ADHD | 1.68 (1.10–2.55) | 0.016 | 1.46 (0.94–2.28) | 0.096 |
| Generalised anxiety disorder | 4.01 (2.34–6.86) | <0.001 | 2.41 (1.35–4.30) | 0.003 |
| Major depressive disorder | 0.23 (0.16–0.33) | <0.001 | 0.31 (0.21–0.47) | <0.001 |
| Outcome 3: Any adverse effect (139/650) | ||||
| Age 4–10 years | Reference | Reference | ||
| Age 11–14 years | 1.25 (0.72–2.17) | 0.427 | 0.90 (0.50–1.62) | 0.728 |
| Age 15–17 years | 1.56 (0.92–2.63) | 0.099 | 0.87 (0.48–1.57) | 0.644 |
| Female sex | 0.77 (0.53–1.13) | 0.180 | – | |
| Prior antidepressant trial | 2.29 (1.41–3.71) | <0.001 | 1.69 (1.00–2.86) | 0.051 |
| Concomitant treatment | 3.80 (2.54–5.69) | <0.001 | 3.32 (2.14–5.16) | <0.001 |
| Major depressive disorder | 1.14 (0.78–1.67) | 0.503 | – | |
| Generalised anxiety disorder | 0.49 (0.30–0.79) | 0.004 | 0.58 (0.35–0.97) | 0.038 |
| ADHD | 1.96 (1.32–2.90) | <0.001 | 1.77 (1.17–2.69) | 0.007 |
| Off-label prescribing | 1.16 (0.75–1.81) | 0.499 | – | |
Variables with p < 0.10 in univariable analysis were entered into the multivariable models. Outcome 1 model: age group and prior antidepressant trial (likelihood-ratio test for age group, p = 0.002; Hosmer–Lemeshow p = 0.608; AUC 0.64). Outcome 2 model: ADHD, GAD and MDD (Hosmer–Lemeshow p = 0.523; AUC 0.71). Outcome 3 model: age group, prior antidepressant trial, concomitant treatment, GAD and ADHD (Hosmer–Lemeshow p = 0.005; AUC 0.71). ‖Not entered into the multivariable model because concomitant agents were frequently added in response to partial improvement (reverse causation). Associations are exploratory and should not be interpreted causally. ADHD, attention-deficit/hyperactivity disorder; aOR, adjusted odds ratio; AUC, area under the receiver operating characteristic curve; CGI-I/S, Clinical Global Impression–Improvement/Severity; CI, confidence interval; GAD, generalised anxiety disorder; MDD, major depressive disorder; OR, odds ratio. p values < 0.05 are statistically significant.